Search Results - "Rébillard, X"

Photodynamic cystoscopy for bladder cancer diagnosis and for NMIBC follow-up: An overview of systematic reviews and meta-analyses by Soorojebally, Y, Neuzillet, Y, Lebret, T, Allory, Y, Descotes, F, Ferlicot, S, Kassab-Chahmi, D, Lamy, P-J, Oudard, S, Rébillard, X, Roy, C, Roumiguié, M, Rouprêt, M, Audenet, F

“…Currently, bladder cancer detection is based on cytology and cystoscopy. White light cystoscopy (WLC) is an invasive procedure and may under-detect flat…”
Get more information

Targeting multiplicity: the key factor for anti-cancer nanoparticles by Gary-Bobo, M, Vaillant, O, Maynadier, M, Basile, I, Gallud, A, El Cheikh, K, Bouffard, E, Morère, A, Rébillard, X, Puche, P, Nirdé, P, Garcia, M

“…In this mini-review, we focus on different strategies to bring nanotools specifically to cancer cells. We discuss about a better targeting of tumor, combining…”
Get more information

Incidence and mortality of urological cancers in 2012 in France by Rébillard, X, Grosclaude, P, Leone, N, Velten, M, Coureau, G, Villers, A, Irani, J, Lebret, T, Rigaud, J, Pfister, C, Patard, J-J, Richaud, P, Salomon, L, Coloby, P, Soulié, M

“…Present national estimations of the incidence and mortality trends in urological cancers in France between 1980 and 2012. Francim database and French Register…”
Get more information

Which non pharmacological interventions should be offered to patients treated with androgen deprivation therapy for prostate cancer? A systematic review by Cecchi, M, Ninot, G, Rebillard, X, Thuret, R, Droupy, S, Ayuso, D, Poinas, G

“…Prostate cancer is a frequent disease and one of the main treatments used is androgen deprivation therapy, which is a therapy with disabling side effects…”
Get more information

Place of partial nephrectomy assisted by robot: Review of the literature at the time of a request for a specific nomenclature by Poinas, G, Long, J-A, Rébillard, X, Descotes, J-L

“…Robot-assisted surgery is practiced more and more frequently in urology. Besides its place in prostatectomy for cancer, it also concerns partial nephrectomy…”
Get more information

Recommendations CCAFU on the management of cancers of the urogenital system during an epidemic with Coronavirus COVID-19 by Méjean, A, Rouprêt, M, Rozet, F, Bensalah, K, Murez, T, Game, X, Rebillard, X, Mallet, R, Faix, A, Mongiat-Artus, P, Fournier, G, Neuzillet, Y

“…The French population is facing the COVID-19 pandemic and the health system have been reoriented in emergency for the care of patients with coronavirus. The…”
Get more information

Health care utilization by men with prostate cancer during the year before their death: A 2015 population-based study by Tanguy-Melac, A, Lesuffleur, T, Fagot-Campagna, A, Gastaldi-Ménager, C, Rébillard, X, Tuppin, P

“…To study the characteristics and health care utilization of men with prostate cancer (PCa) during their last year and last month of life, as these data have…”
Get more information

CCAFU french national guidelines 2016-2018 on prostate cancer by Rozet, F, Hennequin, C, Beauval, J-B, Beuzeboc, P, Cormier, L, Fromont, G, Mongiat-Artus, P, Ouzzane, A, Ploussard, G, Azria, D, Brenot-Rossi, I, Cancel-Tassin, G, Cussenot, O, Lebret, T, Rebillard, X, Soulié, M, Renard-Penna, R, Méjean, A

“…The purpose of the guidelines national committee CCAFU was to propose updated french guidelines for localized and metastatic prostate cancer (PCa). A Medline…”
Get more information

Sexually and Non-sexually Transmitted Infections and The risk of Prostate Cancer by Sawaya, M, Cordinaduverger, E, Lamy, P, Rébillard, X, Tretarre, B, Menegaux, F

“…Abstract Introduction Prostate cancer (PCa) is by far the most common type of cancer among men in western countries. However, relatively little is known about…”
Get full text

Radical prostatectomy for prostate cancer, perioperative management by French urologists in 2018 by Gas, J, Dominique, I, Mathieu, R, Poinas, G, Cuvelier, G, Rebillard, X, Corbel, L

“…Prostatectomy (PT) is a common procedure performed by many urologists. In 2018, 20,207 prostatectomies were performed in France, and few studies evaluated the…”
Get more information

CCAFU Recommendations 2013: Prostate cancer by Salomon, L, Bastide, C, Beuzeboc, P, Cormier, L, Fromont, G, Hennequin, C, Mongiat-Artus, P, Peyromaure, M, Ploussard, G, Renard-Penna, R, Rozet, F, Azria, D, Coloby, P, Molinié, V, Ravery, V, Rebillard, X, Richaud, P, Villers, A, Soulié, M

“…The sub Comittee prostate of the CCAFU established guidelines for diagnostic, treatment, evaluation and standart of care of prostate cancer. Guidelines 2010…”
Get more information

Incidence of Severe Adverse Events After External Beam Radiation Therapy for Prostate Cancer: A Population-Based Study by Delmas, M.C, Hennequin, C, Boussac-Zarebska, M, Lukacs, B, Nicolau, J, Tupin, P, Rebillard, X

“…Purpose/Objective(s)To evaluate the incidence of severe radio induced toxicity on a nation-wide scale (in France).Materials/MethodsUsing data from the French…”
Get full text

Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: Results of the French section of European Randomized Study of Screening for Prostate Cancer (ERSPC) by Villers, A, Bessaoud, F, Trétarre, B, Grosclaude, P, Malavaud, B, Rebillard, X, Iborra, F, Daubisse, L, Malavaud, S, Roobol, M, Heijnsdijk, E A, de Koning, H J, Hugosson, J, Rischmann, P, Soulié, M

“…European Randomized Study of Screening for Prostate Cancer (ERSPC) mortality results were reported for 7 European countries (excluding France) and showed a…”
Get more information

Robot assisted radical prostatectomy: What are the evidences at the time of a specific funding? by Long, J-A, Poinas, G, Fiard, G, Leprêtre, M, Delaitre-Bonnin, C, Rébillard, X, Descotes, J-L

“…Despite a decreasing number of radical prostatectomies in France, the number of robot-assisted surgeries increases. The objective of this work is to assess the…”
Get more information

Changes in therapeutic strategy in metastatic castration resistant prostate cancer (mCRPC) between 2012 and 2014 from the French nationwide claims database (SNDS) by Thurin, N., Rouyer, M., Jové, J., Gross-Goupil, M., Haaser, T., Rebillard, X., Soulié, M., De Pouvourville, G., Capone, C., Pierres, M., Lamarque, S., Bignon, E., Droz-Perroteau, C., Moore, N., Blin, P.

Get full text

Combined Chemoradiation Therapy With Gemcitabine and Cisplatinum for Organ Preservation in Muscle-invasive Bladder Cancer: Long-term Results of a Phase I Trial by Riou, O, Culine, S, Rebillard, X, Thezenas, S, Faix, A, Segui, B, Pouessel, D, Azria, D

Get full text

Updated Results of the Montpellier IMRT Prostate Cancer Cohort: Focus on Elderly Patients by Azria, D, Charissoux, M, Rebillard, X, Fenoglietto, P, Moscardo, C. Llacer, Cristol, L, Hay, M, Ailleres, N, Dubois, J

Get full text

Clinical value of the integration of Prostate Health Index (PHI) in multiparametric MRI-based diagnostic strategies to detect clinically-significant prostate cancer. Results from the French prospective multicenter PHI-1 study by Vlaeminck, V., Rebillard, X., Lamy, P.J., Potiron, E., Colin, P., Irani, J., Roumiguié, M., Vincendeau, S., Cussenot, O., Colombel, M., De La Taille, A., Delagarde, V., Lepers, S., Guechot, J., Armand-Labit, V., Bendavid, C., Dupuis, M., Subtil, F., Huot, L., Ruffion, A.

Get full text

PCN19 Effectiveness and Medical Costs of Abiraterone Acetate Versus Docetaxel in First-LINE Treatment of Metastatic Castration-Resistant Prostate Cancer from the French Nationwide Claims Database (SNDS): Camerra Study by Thurin, N., Rouyer, M., Gross-Goupil, M., Haaser, T., Rébillard, X., Soulie, M., Messaoudi, F., Capone, C., Bignon, E., Lamarque, S., Jové, J., Droz-Perroteau, C., Moore, N., de Pouvourville, G., Blin, P.

Get full text

Guidelines for good practice of intravesical instillations of BCG and mitomycin C from the French national cancer committee (CC-AFU) for non-muscle invasive bladder cancer by Rouprêt, M, Neuzillet, Y, Larré, S, Pignot, G, Coloby, P, Rébillard, X, Mongiat-Artus, P, Chartier-Kastler, E, Soulié, M, Pfister, C

“…Intravesical BCG immunotherapy and mitomycin C are considered as the standard treatment for non-muscle invasive bladder cancer. These guidelines aim to…”
Get more information